CN107708697B - 纤维化病治疗剂 - Google Patents

纤维化病治疗剂 Download PDF

Info

Publication number
CN107708697B
CN107708697B CN201680037175.7A CN201680037175A CN107708697B CN 107708697 B CN107708697 B CN 107708697B CN 201680037175 A CN201680037175 A CN 201680037175A CN 107708697 B CN107708697 B CN 107708697B
Authority
CN
China
Prior art keywords
fibrosis
present
amino
interstitial pneumonia
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680037175.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN107708697A (zh
Inventor
藤冈秋生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Priority to CN202110067291.6A priority Critical patent/CN112716952A/zh
Publication of CN107708697A publication Critical patent/CN107708697A/zh
Application granted granted Critical
Publication of CN107708697B publication Critical patent/CN107708697B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680037175.7A 2015-06-25 2016-06-24 纤维化病治疗剂 Active CN107708697B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110067291.6A CN112716952A (zh) 2015-06-25 2016-06-24 纤维化病治疗剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015-127788 2015-06-25
JP2015127788 2015-06-25
PCT/JP2016/068902 WO2016208744A1 (ja) 2015-06-25 2016-06-24 線維症治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110067291.6A Division CN112716952A (zh) 2015-06-25 2016-06-24 纤维化病治疗剂

Publications (2)

Publication Number Publication Date
CN107708697A CN107708697A (zh) 2018-02-16
CN107708697B true CN107708697B (zh) 2021-02-09

Family

ID=57585165

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680037175.7A Active CN107708697B (zh) 2015-06-25 2016-06-24 纤维化病治疗剂
CN202110067291.6A Pending CN112716952A (zh) 2015-06-25 2016-06-24 纤维化病治疗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110067291.6A Pending CN112716952A (zh) 2015-06-25 2016-06-24 纤维化病治疗剂

Country Status (20)

Country Link
US (4) US10449189B2 (enExample)
EP (2) EP3315131B1 (enExample)
JP (3) JP6974167B2 (enExample)
KR (1) KR102647942B1 (enExample)
CN (2) CN107708697B (enExample)
AU (1) AU2016284531B2 (enExample)
BR (1) BR112017028137B1 (enExample)
CA (1) CA2990791A1 (enExample)
DK (1) DK3315131T3 (enExample)
ES (1) ES2928684T3 (enExample)
HU (1) HUE060732T2 (enExample)
MA (1) MA42266A (enExample)
MX (2) MX381792B (enExample)
MY (1) MY191219A (enExample)
PH (1) PH12017502322B1 (enExample)
PL (1) PL3315131T3 (enExample)
PT (1) PT3315131T (enExample)
RU (1) RU2729630C2 (enExample)
SG (2) SG10201912684TA (enExample)
WO (1) WO2016208744A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112716952A (zh) * 2015-06-25 2021-04-30 大鹏药品工业株式会社 纤维化病治疗剂

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139608A1 (en) 2006-03-14 2007-12-06 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
US12152246B2 (en) 2006-03-14 2024-11-26 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions
DK3583943T3 (da) 2017-02-15 2024-10-14 Taiho Pharmaceutical Co Ltd Farmaceutisk sammensætning
EP3682882A4 (en) 2017-09-08 2021-06-02 Taiho Pharmaceutical Co., Ltd. ANTI-TUMOR AGENT AND ANTI-TUMOR POTENTIALIZER
KR20210060465A (ko) 2018-09-18 2021-05-26 다이호야쿠힌고교 가부시키가이샤 아실티오우레아 화합물과 아비라테론의 병용 요법
TWI872203B (zh) * 2020-02-14 2025-02-11 日商大鵬藥品工業股份有限公司 醯基硫脲化合物的製造方法
CN115177636A (zh) * 2022-07-18 2022-10-14 陕西科美致尚生物科技有限公司 一种用于治疗前列腺钙化的组合物及其制备方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4094814B2 (ja) 1998-04-28 2008-06-04 敏一 中村 血管新生抑制剤
JP2003238592A (ja) * 2001-12-13 2003-08-27 Japan Tobacco Inc 組織及び血管の再生のための医薬及びその方法
EP1896461A2 (en) 2005-06-30 2008-03-12 Amgen Inc. Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
ZA200804681B (en) * 2005-11-30 2009-11-25 Vertex Pharma Inc Inhibitors of C-Met and uses thereof
US7728017B2 (en) * 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EP2215085B1 (en) * 2007-10-25 2011-09-07 AstraZeneca AB Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
JP4667537B2 (ja) 2008-04-10 2011-04-13 大鵬薬品工業株式会社 アシルチオウレア化合物又はその塩、及びその用途
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
MX2012008898A (es) * 2010-02-03 2012-11-06 Incyte Corp Imidazo - [1, 2 - b] [1, 2, 4] triazinas como inhibidores de c - met.
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
RU2494470C1 (ru) * 2012-04-04 2013-09-27 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") Способ лечения фиброза легких
US9149471B2 (en) 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis
BR112017028137B1 (pt) * 2015-06-25 2023-04-04 Taiho Pharmaceutical Co., Ltd Uso de 4-[2-fluoro-4-[[[(2-fenilacetil)amino]tioxometil]amino]- fenóxi]-7-metóxi-n-metil-6-quinolinacarboxamida ou um sal deste

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112716952A (zh) * 2015-06-25 2021-04-30 大鹏药品工业株式会社 纤维化病治疗剂

Also Published As

Publication number Publication date
US20220047572A1 (en) 2022-02-17
JPWO2016208744A1 (ja) 2018-04-12
KR20180021682A (ko) 2018-03-05
SG10201912684TA (en) 2020-03-30
KR102647942B1 (ko) 2024-03-14
AU2016284531A1 (en) 2017-11-30
ES2928684T3 (es) 2022-11-21
PH12017502322B1 (en) 2023-08-30
US10449189B2 (en) 2019-10-22
US20200297716A1 (en) 2020-09-24
PT3315131T (pt) 2022-10-26
EP3315131B1 (en) 2022-09-14
EP3315131A1 (en) 2018-05-02
US11191759B2 (en) 2021-12-07
SG11201709260TA (en) 2018-01-30
MX2017016774A (es) 2018-05-14
DK3315131T3 (da) 2022-11-14
US20180289690A1 (en) 2018-10-11
CN112716952A (zh) 2021-04-30
MY191219A (en) 2022-06-09
JP2022009994A (ja) 2022-01-14
RU2017145271A (ru) 2019-07-25
WO2016208744A1 (ja) 2016-12-29
BR112017028137A2 (pt) 2018-08-28
HUE060732T2 (hu) 2023-04-28
MX381792B (es) 2025-03-13
US11690838B2 (en) 2023-07-04
JP6974167B2 (ja) 2021-12-01
RU2017145271A3 (enExample) 2019-12-02
PH12017502322A1 (en) 2018-06-25
US10695340B2 (en) 2020-06-30
HK1245639A1 (zh) 2018-08-31
MA42266A (fr) 2018-05-02
EP3315131A4 (en) 2019-02-27
MX2020012989A (es) 2021-02-16
JP7498827B2 (ja) 2024-06-12
AU2016284531B2 (en) 2020-06-04
JP7258985B2 (ja) 2023-04-17
EP3973962A1 (en) 2022-03-30
JP2023076632A (ja) 2023-06-01
CN107708697A (zh) 2018-02-16
US20200009128A1 (en) 2020-01-09
BR112017028137B1 (pt) 2023-04-04
RU2729630C2 (ru) 2020-08-11
CA2990791A1 (en) 2016-12-29
PL3315131T3 (pl) 2022-12-12

Similar Documents

Publication Publication Date Title
US11690838B2 (en) Therapeutic agent for fibrosis
WO2001003739A1 (fr) Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
JP5302900B2 (ja) 脂肪性肝疾患の治療用医薬組成物
WO2021257673A2 (en) Methods and compositions for the treatment of muscular dystrophy
KR102843222B1 (ko) 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도
HK40046439A (en) Therapeutic agent for fibrosis
HK1245639B (en) Therapeutic agent for fibrosis
WO2017217071A1 (ja) セレノプロテインｐ活性阻害作用を有する成分を含有する、肺高血圧症の予防又は治療剤
CN113645978A (zh) 用于预防或治疗肺纤维化的药剂
CA2678920C (en) A medicament for treating chronic obstructive pulmonary disease
CN121443299A (zh) 用于治疗脏器纤维化相关疾病的药物组合物和方法
WO2007123126A1 (ja) 慢性心不全における運動耐容能低下の改善剤
JPWO2001003739A1 (ja) スフィンゴシン−１−リン酸受容体アゴニストまたはスフィンゴシン−１−リン酸を有効成分として含有する線維化抑制剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1245639

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant